Bacterial artificial chromosome (BAC)-based transgenes have emerged as a powerful tool for controlled and conditional interrogation of protein function in higher eukaryotes. While homologous recombination-based recombineering methods have streamlined the efficient integration of protein tags onto BAC transgenes, generating precise point mutations has remained less efficient and time-consuming. Here we present a simplified method for inserting point mutations into BAC transgenes requiring a single recombineering step followed by antibiotic selection. This technique, which we call ESI (Exogenous/Synthetic Intronization) mutagenesis, relies on co-integration of a mutation of interest along with a selectable marker gene, the latter of which is harboured in an artificial intron adjacent to the mutation site. Cell lines generated from ESI-mutated BACs express the transgenes equivalently to the endogenous gene, and all cells efficiently splice out the synthetic intron. Thus, ESI-mutagenesis provides a robust
and effective single-step method with high precision and high efficiency for mutating BAC transgenes.
Introduction 1
The ability to precisely query functional hypotheses of protein function in 2 cells requires the capacity to express rationally mutated proteins from genes under 3 their native physiological regulation. Traditionally, transgenes expressed in higher 4 eukaryotes are derived from cDNAs, and thus lack native cis-regulatory elements 5 or alternative splicing isoforms, often resulting in overexpression and 6 deregulation artefacts. This may hinder proper phenotypic functional 7 characterization of mutated genes, as well as the determination of the precise 8 localization and interaction partners of the protein products. While the 9 development of sequence-specific nucleases has enabled mutation of specific 10 genes at their endogenous loci(Gaj et al., 2013; Ran et al., 2013) , mutations in 11 essential genes that are lethal will prevent growth and recovery of viable cells. 12
Additionally, deleterious mutations are prone to accumulate suppressive changes 13 in chromosome integrity or gene expression during the procedure of selecting and 14 expanding cells for analysis, particularly in the genomically instable cancer cell 15 lines frequently employed. attached to a selectable marker gene on a DNA vector has allowed its adaptation to 36 genome-scale high-throughput pipelines (Sarov et al., 2006; Poser et al., 2008; 37 Sarov et al., 2012; Hasse et al., 2016; Sarov et al., 2016) . The subsequent generation 38 of transgenic cell lines based on these libraries has further been used to precisely 39 determine the cellular localisation and the quantitative interactome of more than 40 a thousand proteins (Hubner et al., 2010; Hutchins et al., 2010; Hein et al., 2015) . 41
On the contrary, current techniques to introduce point mutations in BACs still 42 require either a counterselection-based two-step procedure (Bird et al., 2011; 43 Wang et al., 2013) or a lower efficiency one-step procedure requiring extensive 44 PCR-screening (Lyozin et al., 2014) . Here we present a simple and efficient one-45 step procedure to introduce point mutations in BAC transgenes, harnessing 46 introns to carry selectable markers, which reduces the time and cost of generating 47 mutagenized constructs. 48
Modifying intronic sequences is an attractive approach to modifying or 49 gaining gene functionality with minimal perturbation of the host gene protein 50 product, and has met use in a variety of applications such as conditional knock-out 51 and mutant constructs, or miRNA expression (Gu et al., 1994; Kaulich et al., 2015; 52 Wassef et al., 2017) . Synthetic introns have been designed based on the four core 53 splicing signals necessary for spliceosome processing: two splice sites (SS) located 54 at the 5' and 3' intron boundaries (5'SS and 3'SS, respectively), a branchpoint 55 sequence (BP) located approximately 25 nucleotides upstream of the 3'SS, and a 56 polypirimidine tract (PPT) directly upstream of the 3'SS ( Figure 1A ) (Lin et al., 57 2003; Wang and Burge, 2008; Mercer et al., 2015) . Most of the sequence 58 determinants for splicing are thus located within the intron. In most eukaryotes, 59 the consensus sequences of the core splicing elements located within exons are 60 limited to a (C/A) A G sequence directly upstream of the intron and a G 61 downstream of the intron (Figure 1 A) (Zhang, 1998 Here we present a one-step BAC recombineering procedure in which point 67 mutations are introduced into a BAC along with a synthetic intron. An antibiotic-68 resistance gene located within the intron allows the selection of positive clones 69 after the single recombineering step in bacteria, and is seamlessly spliced out of 70 mRNA sequences of the harbouring transgene in eukaryotic cells. This procedure 71 significantly increases the efficiency and decreases the screening time of BAC 72 mutagenesis. 73
74

RESULTS
75
ESI-mutagenesis: a one-step BAC recombineering strategy for introduction 76 of point mutations. 77
The ESI-mutagenesis strategy is outlined in Figure 1 . First, a synthetic 78 intron "cassette" is amplified by PCR for use in the recombineering reaction ( Fig  79   1B ). This synthetic intron cassette contains the core intron-based splicing signal 80 sequences, as well as an antibiotic resistance gene. We have created multiple 81 cassettes with varying bacterial and eukaryotic selectable markers, presented in 82 Figure S1 . In order to become a functional intron, the synthetic intron cassette 83 must be recombined into a site in the exon where it is directly bordered by an 84 upstream (C/A) A G sequence and a downstream G ( Figure 1A , and C). While this 85 (C/A) A G | G sequence would occur every 128 nucleotides assuming random 86 distribution, similar sequences can be mutated to this sequence at amino acid 87 wobble positions during cassette amplification (see Figure S2 for an example), 88 significantly increasing the frequency of useable integration sites. Furthermore, 89 this consensus is not a strict requirement, and a variety of sequences are found in 90 cells and predicted to function (Zhang, 1998; Nguyen et al., 2018; Ohno et al., 2018) . 91 Therefore, it is unlikely that a potential synthetic intron integration site will not be 92 found within the useable vicinity of a mutation site of interest. In addition, if the 93 desired mutation is close enough to an existing intron, the antibiotic resistance 94 cassette can be directly targeted to the endogenous intron by generating only one 95 new splice site, with the opposite homology arms targeting intronic sequences (see 96 Figure 1C , right side). This is preferable when possible, because not only does it 97 maintain more closely the native intron/exon structure, but it also avoids the 98 creation of unusually small exons (less than ~50bp), which may be prone to exon 99 skipping (Dominski and Kole, 1991). 100 101 An example of how to design ESI-mutagenesis is presented in supplementary 102 Figure S2 . Once a target site for synthetic intron insertion near the mutation site is 103 identified, primers are designed to amplify the synthetic intron cassette and 104 containing 5'-extended 50 bp arms homologous to sequences directly surrounding 105 the insertion site. One or both homology arms contain the mutation(s) to be 106 integrated. The cassette is amplified by PCR and the resulting product is inserted 107 into the target BAC via recombineering (Figure 1 C). Correct recombination events 108 are selected using the antibiotic resistance encoded within the synthetic intron. A 109 protocol for the ESI mutagenesis recombineering procedure as well as generating 110 mammalian transgenic cell lines is provided in Figure S3 . 111 112 Upon transfection of the modified BAC into eukaryotic cells of interest, cells that 113 have integrated the BAC in their genome may also be selected using the antibiotic 114 resistance encoded within the synthetic intron. If desired, the antibiotic resistance 115 gene may be removed by application of Cre recombinase via loxP sites located 116 within the cassette ( Figure S1 ). Once the BAC transgene is transcribed the 117 synthetic intron is spliced out leading to the formation of a messenger RNA 118 carrying the desired mutation. To confirm that BAC transgenes containing synthetic introns yielded 123 proteins of the correct size and localisation when expressed in human cells, we 124 started with a panel of 10 GFP-tagged BAC transgenes, and modified each using our 125 ESI-mutagenesis strategy to introduce mutations to render them resistant to 126 specific siRNA targeting sequences (Table S1 ). We then generated Hela cell lines 127 stably expressing either the "parental" GFP-tagged genes, or the "ESI-mutated" (i.e. 128
RNAi-resistant) GFP-tagged genes (Figure 2A ). Because these mutations should 129 not change the corresponding protein sequence, this allowed us to directly 130 compare the expression and localization of the mutated transgenes to that of the 131 parental, while offering an assay for the presence and function of the introduced 132 mutation (RNAi resistance). Depending on the location of the mutation with 133 respect to an existing intron, we either targeted the synthetic intron along with the 134 desired mutation into an exon (4/10 BACs) ( To further demonstrate that ESI-mutagenesis allows the introduction of functional 157 mutations in a BAC transgene, we used the procedure to mutate two EB1-158 interacting motifs (SxIP) of the microtubule-associated protein GTSE1 to abolish 159 its interaction with the plus end tracking protein EB1 (Honnappa et al., 2009; Scolz 160 et al., 2012) . In this example, we started with a GFP-tagged GTSE1 BAC, integrated 161 the synthetic intron between the two sites to be mutated, and included the two 162 mutations (SxNN) within the 5' and 3' homology arms ( Figure S2 ). U2OS cells were 163 generated stably expressing the BAC transgene and analysed for GTSE1 expression 164 and interaction with EB1. The ESI-mutated BAC yielded a protein of the same size 165 as GTSE1 endogenously tagged with GFP, as expected ( 
A functional ESI-mutated BAC transgene is expressed in all cells of a clonal 172 line 173
We showed above that ESI-mutated BACs yield proteins of the expected size 174 and the correct cellular localisation, and that mutation may efficiently confer RNA-175 resistance or loss of interaction partner when analysed at the cell-population level. 176
We next further assessed whether an ESI-mutated transgene was functionally 177 expressed, i.e. able to sustain the cellular functions of its endogenous counterpart, 178 uniformly in all the cells of a population. This is critical for functional and 179 phenotypic analysis of mutants on the single cell level. To address this question, 180
we ESI-mutated the gene encoding Aurora A kinase (AURKA) on a GFP-tagged BAC 181 transgene to render it resistant to RNAi, transfected it into U2OS cells, and selected 182 a cell clone (U2OS AURKA-GFP siRES (ESI)) that expressed Aurora A-GFP at the 183 same level as the endogenous Aurora A ( to-transfect cell lines where extensive screening may be necessary without a 258 selection step. In our preliminary studies applying this ESI-mutagenesis strategy 259 to direct Cas9-mediated human genome modification, we are indeed able to 260 recover modified cell lines at high frequency. We also found, however, more readily 261 observable impacts on gene expression from the synthetic intron when located in 262 the native gene, which could be alleviated by removing the antibiotic resistance 263 gene after Cre application. While further development of the synthetic intron 264 cassette design/strategy towards direct genome modification holds promise for 265 high efficiency selection of Cas9-mediated site-directed mutation, sensitive 266 applications (i.e. anything to be used in a clinical setting) would not be advisable 267 due to potential changes induced by the synthetic intron. All BACs used and generated, including modified sequences, are presented in 277 Table S1 . LAP-and NLAP-tagged "parental" BACs were generated by 278 recombineering as described in Poser et al 2008. "ESI-mutated" BACs were 279 generated from "parental" BACs following the procedure outlined in Figure S3 . Duration of the depletion is indicated for each gene in Table S1 . 333 334
Western Blot 335
Cells were lysed on ice for 10 to 15 min in RIPA buffer or cell lysis buffer (50 mM 336 Na2HPO4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1. For most experiments, cells were seeded onto coverslips and fixed in ice-cold 368 methanol for 12 min at -20 °C. Cells were blocked at RT with 5% BSA (Sigma) 369 dissolved into PBS. For images of Aurora B-GFP and CHMP4B-GFP cell lines, cells 370 were fixed in 3% PFA supplemented with 5 mM EGTA, 1mM MgCl2 and 2% 371 sucrose, they were washed, then permeabilized using PBS/0.1% Triton X-100 and 372 eventually blocked with PBS/0.2% Fish Skin Gelatin (Sigma, Germany). Primary 373 antibodies were diluted into 5% BSA in PBS and incubated onto coverslips for 1 h 374 at 37 °C in a wet chamber. The same procedure was applied for secondary antibodies. 375
Coverslips were mounted using Prolong Gold antifade mounting with DAPI (Molecular 376
Probes and Thermo Fisher Scientific). Cells were washed thrice with PBS between 377 every step. ESI mutagenesis is a one step recombineering procedure that relies on the 519 introduction into a BAC of a synthetic intron coding a selectable marker along with 520 the mutation of interest, thereby allowing for the easy selection of correct 521 recombinants. After transcription of the transgene in eukaryotic cells, the 522 synthetic intron is spliced out to produce a mutated mRNA. Figure S3 
